November 12, 2020 -- WuXi Advanced Therapies has expanded its cell and gene therapy platforms with capabilities to provide high-quality and cost-effective good manufacturing practice (GMP) plasmids.
With these enhanced capabilities, the company can assist customers in overcoming current plasmid DNA supply constraints and expediting research and development and manufacturing processes of cell and gene therapy applications. WuXi is able to leverage its experience in testing of raw materials and biotherapeutics as well as in-house quality control and analytical services to ensure the safety of well-characterized and fully released plasmids.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
